Durect Corporation (DRRX) has been under a strong bear grip, hence the stock is down -11.43% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.25% in the past 1 week. The stock has risen by 3.8% in the past week indicating that the buyers are active at lower levels, but the stock is down -13.23% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 3.59% and the 50-Day Moving Average is 2.97%.The 200 Day SMA reached 10.09% DURECT Corporation is up 36.67% in the last 3-month period. Year-to-Date the stock performance stands at -25.79%.
Durect Corporation (DRRX) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $6 and the lowest price target forecast is $4. The average forecast of all the analysts is $5 and the expected standard deviation is $1.41.
For the current week, the company shares have a recommendation consensus of Buy. Durect Corporation (NASDAQ:DRRX): The stock opened at $1.62 and touched an intraday high of $1.68 on Friday. During the day, the stock corrected to an intraday low of $1.58, however, the bulls stepped in and pushed the price higher to close in the green at $1.64 with a gain of 3.14% for the day. The total traded volume for the day was 1,285,502. The stock had closed at $1.64 in the previous trading session.
Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms, chemical entities derived from its Epigenomic Regulator Program, and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs, in which it applies its formulation and technologies to pharmaceutical ingredients, and New Chemical Entities derived from its Epigenomic Regulator Program, in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone), POSIDUR (SABER-Bupivacaine), ELADUR (TRANSDUR-Bupivacaine), Relday, ORADUR-ADHD, ORADUR-Opioid and SABER-based ophthalmic.